1. Introduction {#s0005}
===============

Development of antimicrobial resistance is a challenging problem in world health scenario, despite the increasing demand for antimicrobials in global pharmaceutical market worths a current value of about \$66.5 billions [@bib1]. However, antibiotics are one of the most widely used and frequently misused drugs. Due to wide predominance of infectious diseases and emergence of resistant strains, there is an increased inclination among clinicians to prefer newer-generation antibiotics as one of the first-line therapeutic regimens. However, prolonged antibiotic therapy may give rise to some side effects like anemia, dyspepsia, hyperacidity, gastritis, hepatotoxicity and nephrotoxicity, which necessitate co-medications. Such co-medications include common antacids or multivitamins (MVs) which are either prescribed by physicians or self-advised and that may adversely affect the bioavailability of the antibiotic prescribed. Thus, the anti-microbial effect of the drug is compromised, leading to prolonged consumption of the antibiotic and development of antimicrobial resistance against that particular antibiotic [@bib2], [@bib3], [@bib4].

Fluoroquinolones administered orally have been a preferred choice for clinicians in treatment of grave infections for decades. Ciprofloxacin (CPFX) is a fluoroquinolone carboxylic acid derivative and broad-spectrum antibiotic active against Gram-positive and Gram-negative organisms. Pharmacokinetically, CPFX undergoes renal and hepatic bio-degradative pathways. After 24 h of administration, approximately 50% of oral dosage or 80% of intravenous dosage appears in the urine either as parent compounds or as metabolites. Renal excretion of CPFX is nearly thrice the glomerular filtration rate, highlighting the role of tubular secretion and anionic transport mechanism in the elimination of this carboxyfluoroquinolone. As a popular oral antibiotic with rapid onset of action, it is used in treatment of numerous infectious diseases afflicting the skin, bones, gastrointestinal tract (GI-tract), genitourinary tract, and meninges. Mechanistically, CPFX acts by effective inhibition of DNA gyrase preventing DNA replication in susceptible bacteria [@bib5]. Patients under prolonged CPFX therapy are reported to suffer from hyperacidity, nausea, vomiting, gastritis, pain in the abdomen, and anemia and hence they consume antacids often without medical supervision. Calcium or magnesium containing antacids is more popular among the consumers than the H~2~ antagonists or proton pump inhibitors. Calcium carbonate tablets or supplements are widely consumed by patients with osteoporosis or bone-related disorders for therapeutic purpose. Similar is the case with intake of calcium-rich foods like milk or yogurt providing dietary supplementation of osteo-calcium. Anemia is another side effect with the sustained use of CPFX and the preventive measure goes to prescribing MVs. Sometimes, secondary disease conditions also necessitate the rational use of MVs along with CPFX. MVs affect the bioavailability of the drug, leading to further research to make it evidence based [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8]. Indians are mainly lacto-vegetarian and use milk as a culturally acceptable measure for various conditions of GI tract disorders and anemia.

The current research work aims at detecting the quantitative effect of calcium (Ca), MVs and milk on the elimination of single-dose CPFX in the urine of human volunteers by UV and HPLC. Further research will be extended to see CPFX interactions with Ca, milk and MVs by *in vitro* dissolution studies and establish *in vitro*--*in vivo* correlation (IVIVC) which is a predictive mathematical treatment describing the relationship between an *in vitro* property of a dosage form (*e.g.* extent of drug release) and a relevant *in vivo* response (*e.g.* amount of drug absorbed) [@bib9], [@bib10], [@bib11]. In ciprofloxacin assessment, urinary samples were preferred to blood samples considering volunteer׳s compliance, convenient methodology, concentration of drugs in the urine being higher than in the blood, detection that can be made by simple analytical methods of UV, lack of protein in the urine of a healthy volunteer obviating the need for denaturation step, and no extra sample pretreatment (the only caution is to look after urine dilutions) [@bib12], [@bib13], [@bib14], [@bib15], [@bib16]. A novel applicational aspect of the current research was to establish IVIVC using dissolution test as a surrogate for *in vivo* CPFX interactions and bioavailability studies, which can waive the need for expensive human trials and hence is a suitable substitute for bioequivalence studies [@bib9], [@bib10], [@bib11], [@bib15], [@bib16].

2. Materials and methods {#s0010}
========================

2.1. Chemicals and reagents {#s0015}
---------------------------

All solvents used were of HPLC grade and reagents were of analytical grade. HPLC grade water was used. Reagents as specified like phosphoric acid, triethylamine and acetonitrile were purchased from Merck and Sigma (Mumbai, India). CPFX was a gift sample from M/s East India Pharmaceuticals Ltd., Kolkata and Lomefloxacin (internal standard, IS) from Macleods (Mumbai, India). CPFX film coated tablets (500 mg), calcium tablets (500 mg) and multivitamin syrup (Polybion^®^) were purchased from the local market. Packed fresh cow milk was obtained from local dairy. Each 5 mL of Polybion syrup contained vitamin B~1~, 2 mg; vitamin B~2~, 2.5 mg; vitamin B~6~, 0.75 mg; nicotinamide, 15 mg; pantothenyl alcohol, 3 mg; and vitamin-B~12~, 2 mg. The syrup specification of MV content was 16.03 for 100 mL, 34.28 for 250 mL, and 52.27 for 400 mL.

2.2. Instrumentation {#s0020}
--------------------

UV spectrophotometric determinations were done in Thermo Scientific (Mumbai, India). HPLC analyses were carried out in Shimadzu LC 10 ADVp (Japan) with UV detector, and dissolution studies were performed using USP Type ІІ dissolution test apparatus (Labindia DS 8000, Mumbai, India).

2.3. Volunteer selection and urine collection {#s0025}
---------------------------------------------

The study protocol followed the ethical principles for bio-medical research involving human volunteers (ICMR 2009). Healthy adult human volunteers (four males and females each) of 25--35 years were selected (lottery) from a pool of 25 volunteers residing locally with the body weight of 65--78 kg. Study time was winter season. Volunteers were clinically assessed by physicians of School of Medical Science and Technology, IIT Kharagpur. Anthropometric status, blood biochemistry and hematology values were within the normal limits in all these subjects. Smokers, alcoholics, those with enzyme deficiencies, particularly renal and hepatic insufficiencies, children, pregnant and lactating women, non-cooperative and inconsistent individuals were excluded from the study. Written consents of eight volunteers were obtained after explaining them the research protocol in vernacular. The volunteers were asked to maintain standard dietary conditions (avoiding high caloric and junk food), definite water (1 L) intake, normal physical activities, and avoidance of strenuous exercises and work overloads in the ensuing days of study.

The volunteers were given one CPFX tablet (500 mg) on the first day; one CPFX tablet (500 mg) and vitamin B-complex (Polybion, 15 mL) on the third day (out of four days of trial, a gap of one day was kept between each day of trial so as to ensure complete renal clearance of CPFX); one CPFX tablet (500 mg) and calcium tablet (Calbon 500, Saga Lab; calcium carbonate 1.25 g) on the fifth day; and one CPFX tablet (500 mg) and 250 mL of cow-milk immediately after tablet intake on the seventh day and no other food or drink was ingested for the next 6 h on the seventh day. Midstream urine samples of the eight volunteers were collected in sterilized vials properly labeled on four days of drug intake maintaining the same time intervals (2, 4, 8, 12, and 16 h), stored in refrigerator and protected from light.

In order to get reproducible urinary excretion studies, water loading was done by ingesting 400 mL of water to the volunteers after overnight fasting prior to the trial to promote diuresis and enable collection of sufficient urine samples [@bib12]. Before drug administration, the volunteers were instructed to ensure complete urination; 1 h after water loading, the urine sample collected at this time was taken as the blank sample. The volunteers were instructed to take CPFX with 200 mL of water, followed by another 200 mL given at hour intervals for the next 4 h. The same procedures were used for the four days of drug intake of trials and the volunteers were instructed for complete emptying of the bladders to collect sufficient urine samples [@bib12], [@bib15].

2.4. UV spectrophotometric analysis of urine samples {#s0030}
----------------------------------------------------

The UV analysis of the urine samples collected from the volunteers at different time intervals was carried out in the following manner. Urine samples (0.4 mL) collected at different time intervals were diluted with 20 mL of methanol: water (80:20, v/v). The samples were scanned using the same diluents (methanol: water, 80:20, v/v) as blank and the wavelength range was fixed between 200 and 400 nm [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21].

For the quantitative estimation of CPFX release under different study conditions, 0.4 mL of urine was diluted to 20 mL. The volume of urine collected in each case was 50 mL. UV absorbance values of 0.4 mL of diluted urine samples at different time intervals (2, 4, 8, 12, and 16 h) were plotted in the standard calibration curve of CPFX and intrapolated to get the corresponding concentration of CPFX. Thus, the amount of CPFX present in 50 mL of urine samples was calculated by unitary method.

2.5. HPLC analysis of the urine samples {#s0035}
---------------------------------------

HPLC analysis was carried out using inertsil ODS C~18~ column, (150mm×4.6mm, 5 µm) maintaining a column temperature of 20 °C, injection volume of 10 µL with a flow rate of 1.2 mL/min, and a run time of 10 min. The UV detector was set at a wavelength of 278 nm.

A 7 mL of triethylamine was diluted in 1000 mL of HPLC grade water and then adjusted to a pH of 3.0 with phosphoric acid, well mixed and degassed. The mobile phase consisted of a filtered and degassed mixture of 0.025 M H~3~PO~4~ (adjusted to a pH of 3.0 with triethylamine) and acetonitrile in the ratio of 87:13 (v/v).

In HPLC studies, quantitative estimation of CPFX release under different study conditions was determined according to the following equation:$$\%\text{assay} = \frac{A_{t} \times W_{s} \times D_{t} \times P \times A_{w}}{A_{S} \times W_{t} \times D_{s}} \times 100$$where *A*~t~ is the average area of major peak in test chromatogram, *A*~s~ is the average area of major peak in standard CPFX chromatogram, *W*~t~ is the wt of test taken in mg (to get from HPLC calibration curve), *W*~s~ is the wt of std CPFX taken in mg (11/30/60 mg), *P* is the purity of working standard (99.5%), *D*~t~ is the dilution of test samples (50 times diluted), *D*~s~ is the dilution of standard solution, and *A*~w~ is the average wt of tablet (500 mg).

2.6. Dissolution studies {#s0040}
------------------------

Absorption and hence bioavailability of the drug greatly depend on the dissolved state of the drug. Therefore, dissolution rate is a critical step in the performance of a drug and its dosage forms. This step of a drug is found to be affected by co-administered drugs and other food ingredients [@bib9], [@bib10], [@bib14], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26].

*In vitro* CPFX interaction with calcium, MVs and milk was studied in USP Type ІІ dissolution test apparatus with certain modifications of the reported literature [@bib24], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31]. Briefly, dissolution study of CPFX tablets was carried out in 500 mL of dissolution media under simulated gastric and intestinal pH conditions (pH 1.2 and 6.8, respectively), thermostated at 37±5 °C and operated at 100 rpm. 5 mL of aliquots of dissolution media were withdrawn at predetermined time intervals (5, 15, 30, 45, 60, 90 and 120 min) and their absorbance was measured at 276 nm in UV spectrophotometer.

For testing the action of calcium on the dissolution behavior of CPFX, calcium tablet was added to the dissolution medium with an appropriate concentration of CPFX at the start of the experiment while other conditions remained the same. Aliquots of the dissolution medium were withdrawn and CPFX concentrations were determined spectrophotometrically at 276 nm.

*In vitro* milk--CPFX interaction studies were conducted in 500 mL of dissolution media, and other conditions remained the same as above. One FDA glass (250 mL) of low fat milk was added to the dissolution media with an appropriate concentration of CPFX at the start of the experiment; CPFX concentrations were determined spectrophotometrically at 276 nm.

*In vitro* MVs--CPFX interaction studies were conducted in 500 mL of dissolution media, and other conditions remained as before. A 55 mL of Polybion syrup was added to the dissolution media with an appropriate concentration of CPFX at the start of the experiment; CPFX concentrations were determined spectrophotometrically at 276 nm. In all the above *in vitro* dissolution studies, the aliquots withdrawn were not replenished with fresh equivalent amount of dissolution media.

Cumulative percentage of CPFX release profiles was characterized by the area under the dissolution curves (AUC) up to a time '*t*' in simulated gastric and intestinal fluids (SGF and SIF) under different study conditions. The AUC for each dissolution profile was calculated by the trapezoidal rule [@bib32], [@bib33], [@bib34].

2.7. Comparison of dissolution data {#s0045}
-----------------------------------

The dissolution profiles were further analyzed by difference factor (*f*1) and similarity factor (*f*2). Difference factor (*f*1) is the percentage difference between two curves at each point and is a measurement of the relative error between the two curves. The similarity factor (*f*2) is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent dissolution between the two curves [@bib35], [@bib36], [@bib37]. The following equations were used to calculate *f*1 and *f*2 values:$$f1 = \left\{ {\left\lbrack \left. \Sigma_{t = 1}n \middle| R_{t}–T_{t} \right| \right\rbrack/\left\lbrack {{\Sigma_{t = 1}}^{n}R_{t}} \right\rbrack} \right\} \times 100$$$$f2 = 50X\log{\{{{\lbrack{1 + {({1/n})}{\Sigma_{t = 1}}^{n}{({R_{t}–T_{t}})}^{2}}\rbrack}^{- 0.5} \times 100}\}}$$where *n* is the number of points, *R*~*t*~ is the dissolution value of the reference product at time *t*, and *T*~*t*~ is the dissolution value for the test product at time *t*. For dissolution curves to be considered similar, *f*1 should be close to zero and *f*2 should be close to 100. Generally, *f*1 value ranges up to 15 (0--15) and *f*2 values are greater than 50 (50--100), which ensures equivalence between the two curves.

In this research, CPFX was used as the standard substance and CPFX+Ca, CPFX+MVs and CPFX+milk were used as the reference substances. Comparison was made for both *in vitro* SIF and SGF conditions using *f*2 values. The more the deviation from the standard value, the greater the accuracy of the experimental methodology.

2.8. IVIVC studies {#s0050}
------------------

IVIVC is a predictive mathematical treatment describing the relationship between *in vitro* properties of a dosage form (*e.g.* extent of drug release) and a relevant *in vivo* response (plasma drug concentration or amount of drug absorbed). IVIVC has drawn the attention and is worthy of consideration by pharmaceutical industries, academics and regulatory sectors. If *in vitro* tests can suitably reflect bioavailability data, it is helpful to waive bioequivalence studies on healthy volunteers. Among the three main levels (A, B and C) of IVIVC, level A (the highest grade) relates the entire *in vitro* dissolution curve to *in vivo* concentration profile (*in vivo* absorption curve) so that *in vitro* dissolution can serve as a surrogate marker for *in vivo* drug actions study; level B of IVIVC utilizes Statistical Moments Analysis to compare the mean of any parameter of *in vitro* dissolution (*e.g.* mean dissolution time, MDT~*in\ vitro*~) with the mean of any *in vivo* parameter (*e.g.* mean residence time, MRT~*in\ vivo*~); level C of IVIVC establishes a single point correlation between an *in vitro* dissolution parameter (*e.g.* time to release 50% or 90% of the active drug, *T*~50%~ or *T*~90%~) and corresponding *in vivo* parameter (*e.g. C*~max~, *T*~max~ or AUC) [@bib9], [@bib10], [@bib11], [@bib32], [@bib38], [@bib39], [@bib40], [@bib41].

In this study, IVIVC was determined by plotting the percentage of CPFX released (CPFX~rel~) *in vitro* (from dissolution studies) against the cumulative percentage of CPFX excreted in urine for a sufficient period of time which is directly related to the total amount of CPFX absorbed.

3. Results {#s0055}
==========

The mean (±SD) values of various parameters of the eight volunteers were determined as follows: age, 27.3±4.16 years; weight, 69.5±8.01 kg; height, 170.3±6.45 cm; body surface area (BSA), 1.7±6.95 m^2^; systolic blood pressure, 123±0.82 mmHg; and diastolic blood pressure, 80±0.91 mmHg. Linearity details of the standard calibration curves of CPFX for UV, HPLC and dissolution studies are presented in [Table 1](#t0005){ref-type="table"}. The quantitative elimination of CPFX at hourly intervals (2, 4, 8, 12, and 16 h) was determined from the standard calibration curve of UV and HPLC studies and is shown in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}. The peak areas (±SD) values of CPFX eliminated at hourly intervals in the urine of eight volunteers as detected in HPLC analysis are provided in [Table 2](#t0010){ref-type="table"}. The pharmacokinetic parameters determined from the urinary excretion data obtained from UV and HPLC studies are summarized in [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}. The *in vitro* cumulative CPFX elimination in SGF and SIF under different study conditions is shown in [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"} and Suppl. [Figs. 1 and 2](#s0070){ref-type="fn"}. Comparisons of dissolution profiles under different study conditions both in SGF and SIF were made based on *f*2 values. *f*2 values in SGF were 35.81 (CPFX+Ca), 29.77 (CPFX+milk) and 31.31 (CPFX+MVs), and in SIF they were found to be 36.36 (CPFX+Ca), 31.2 (CPFX+milk) and 32.16 (CPFX+MVs). For IVIVIC studies, the correlation coefficient of CPFX release both *in vitro* (dissolution studies) and *in vivo* (urinary excretion studies) are presented in [Table 7](#t0035){ref-type="table"} and Suppl. [Figs. 3--6](#s0070){ref-type="fn"}.Fig. 1Quantitative elimination of CPFX at hourly intervals under different study conditions (UV studies).Fig. 2Quantitative elimination of CPFX at hourly intervals under different study conditions (HPLC studies).Fig. 3Cumulative elimination of CPFX under different study conditions (HPLC studies).Table 1Data of calibration curve of CPFX for UV, HPLC and dissolution studies.ParametersUV studiesHPLC studiesDissolution studies95% confidence intervals Slope0.105--0.10812.82--13.780.141--0.163 *Y*-intercept−0.0013--0.0109−11.84--22.54−0.0406--0.0468 *X*-intercept−0.103--0.0125−1.748--0.864−0.330--0.250  Goodness of fit *R*^2^0.9990.9990.997 *P* value\<0.0001\<0.0001\<0.0001 Equation*Y*=0.1072*X*+0.004*Y*=13.30*X*+5.348*Y*=0.1522*X*+0.003  Best fit values Slope (±SD)0.1072±0.000413.30±0.180.1522±0.004 *Y*-intercept (±SD)0.004785±0.0025.348±6.680.003133±0.015 *X*-intercept−0.0446−0.402−0.0205Table 2Peak area values of CPFX eliminated in the urine of the 8 volunteers in HPLC studies under different conditions.Time (h)CPFX aloneCPFX+MVsCPFX+calciumCPFX+milk23411±1853184±1871893±1532430±15742027±2105990±3003073±2623372±19081374±3911254±951382±3101746±14612857±299923±1771009±154954±187[^1]Table 3Pharmacokinetic parameters of urinary excretion data by UV.Pharmacokinetic parametersCPFX (alone)CPFX+MVsCPFX+CaCPFX+milkAUC~0−*t*~ (μg/mL h)8903.9210,238.649490.739742.78AUC~0−*α*~ (μg/mL h)11,702.8313,121.1112,237.1712,196.97*t*~1/2~ (h)3.2033.1013.1183.067*k*~a~ (1/h)0.24400.25680.25290.2768Cl/F (mg)/((μg/mL)/h)0.042720.038100.040850.04099*C*~max~ (μg/mL)988.211154.621065.871118.50*T*~max~ (h)4.3484.1704.2143.991AUMC (μg/mL h^2^)102,029.75109,795.28103,441.4698,026.88MRT (h)8.7188.3678.4538.037Table 4Pharmacokinetic parameters of urinary excretion data by HPLC.Pharmacokinetic valuesCPFX (alone)CPFX+MVsCPFX+CaCPFX+milkAUC~0--*t*~ (μg/mL h)924.871897.501527.871515.68AUC~0--*α*~ (μg/mL h)1531.317204.612342.381515.68*t*~1/2~ (h)4.21226.5844.2450.327*k*~a~ (1/h)0.1753.6320.2144.235Cl/F (mg)/((μg/mL)/h)0.32650.06940.21340.3298*C*~max~ (μg/mL)95.64181.26160.121603.94*T*~max~ (h)5.8871.3685.3320.327AUMC (μg/mL h^2^)18,042.98278,306.3125,287.541074.26MRT (h)11.78238.62810.7950.709Table 5*In vitro* data of CPFX release in SGF (dissolution studies).Time (min)CPFX[a](#tbl5fna){ref-type="table-fn"}CPFX+Ca[b](#tbl5fnb){ref-type="table-fn"}CPFX+milkCPFX+MVs[c](#tbl5fnc){ref-type="table-fn"}00000526.808.145.78.11538.2036.5412.810.93050.4540.9115.416.74566.5042.1516.922.96070.2342.9125.329.49082.4545.0128.132.112098.0147.2430.935.5[^2][^3][^4]Table 6*In vitro* data of CPFX release in SIF (dissolution studies).Time (min)CPFX[a](#tbl6fna){ref-type="table-fn"}CPFX+Ca[b](#tbl6fnb){ref-type="table-fn"}CPFX+ milkCPFX+MVs[c](#tbl6fnc){ref-type="table-fn"}00000527.110.66.25.91543.525.311.110.73057.832.412.718.14573.539.016.724.26080.145.222.828.09092.747.431.534.512099.049.536.238.9[^5][^6][^7]Table 7Correlation coefficient (*R*^2^) values obtained from IVIVC data of CPFX release under different conditions.MediaCPFX[a](#tbl7fna){ref-type="table-fn"}CPFX+MVs[b](#tbl7fnb){ref-type="table-fn"}CPFX+Ca[c](#tbl7fnc){ref-type="table-fn"}CPFX+milkUV methodSGF--urine0.9990.9180.6640.908SIF--urine0.9970.9530.7860.974  HPLC methodSGF--urine0.9840.8600.6510.899SIF--urine0.9950.9240.8010.951[^8][^9][^10]

4. Discussion {#s0060}
=============

Our research data showed that elimination of CPFX (either cumulative release or at hourly intervals) increased significantly when co-administered with MVs, Ca-tablets and milk as evident by *in vivo* UV and HPLC urinary excretion studies and *in vitro* dissolution studies. Elimination of CPFX was markedly increased in the order of MVs\>milk\>calcium in contrast to CPFX release when administered alone.

Analyses of pharmacokinetic parameters showed that an increase in *k*~a~ values increased the *C*~max~ and *vice versa*. In contrast, *T*~max~ values were found longer with smaller *k*~a~ values and shorter with larger *k*~a~ values. However, *k*~a~ values did not show any influence on the AUC.

The similarity factor, *f*2 values, ranged from 29.77 to 36.36, suggesting the accuracy of our *in vitro* experimental methodology [@bib35], [@bib36], [@bib37]. From the point of IVIVC studies, our research data showed *R*^2^ values ranging from 0.651 to 0.999 under different study conditions, thus exhibiting a good correlation. Estimation of CPFX elimination under different conditions and determination of the IVIVC based on urinary excretion data were found to be simple, reliable and cost-effective. The simultaneous dissolution studies could serve as a bio-waiver for expensive human trials and hence this method could be a suitable substitute for bioequivalence studies. Dissolution studies can serve as a surrogate for *in vivo* bioavailability and support bio-waivers.

Prolonged antibiotic therapy causes anemia, gastric irritation or acidity; thus, antacids and multi-vitamin formulations are the commonly co-administered drugs with antibiotics [@bib1], [@bib5], [@bib8]. Calcium either in the form of carbonate or chloride is a constituent of many marketed antacid formulations [@bib2], [@bib3], [@bib42], [@bib43]. Multivitamin formulations, especially with mineral contents, are found to reduce the bioavailability of fluoroquinolones [@bib4], [@bib5], [@bib8]. It is a common practice of many patients to intake drugs with drinks like milk, yogurt or juices other than water. Moreover, calcium-enriched foods and dairy products are often included in the breakfast menu of patients undergoing treatment [@bib6], [@bib7], [@bib24]. Our research findings showed that the bioavailability of CPFX was significantly reduced by co-administration of MVs followed by that of milk and calcium. Calcium or its salts chelates or binds with CPFX, preventing its absorption and thereby reducing its bioavailability. However, milk was found to inhibit absorption of CPFX more than calcium alone mostly because of CPFX interactions with the milk matrix which decreased CPFX absorption by complexation with metal ions present in milk and by adsorption at the surface of milk protein molecules mostly casein (forms \~84% of total milk protein), thus providing additional inhibitory effect and preventing absorption of CPFX [@bib24]. Structurally, each CPFX molecule has one R−COOH group which readily interacts with Ca^2+^ ions (also other poly cations) [@bib41]. The R--COOH group of CPFX becomes negatively charged, releasing H^+^ ion, determined by its p*K*~a~ value. The p*K*~a~ for carboxyl groups ranges between 1.8 and 2.4 [@bib12], [@bib13]. Thus, a pH above this p*K*~a~ would result in a greater percentage of the carboxyl groups on CPFX being ionized. Depending on other mechanisms like intake of antacids containing metals like calcium, H~2~ antagonists, proton pump inhibitors; the type of food ingested by the patient; and the pH of the stomach which mostly ranges from 1 to 6, it is likely that the p*K*~a~ of the carboxyl group will be exceeded [@bib13], [@bib41]. However, if the patient takes only CaCO~3~ containing formulations with CPFX on an empty stomach, CaCO~3~ can interact with gastric HCl to form CaCl~2~, CO~2~ and H~2~O, thus increasing the gastric pH value. Therefore, the magnitude of change in gastric pH, whether it is from CaCO~3~ itself or from combination of CaCO~3~ and other medications, can influence the amount of ionized carboxyl groups found on CPFX. Owing to such ionization, the exposed and negatively charged groups on CPFX bind with the positively charged Ca^2+^ ions that are present in the medication or supplement administered, referred to as chelation. The degree or significance of this interaction is, however, dependent on the time of exposure to one another and the pH of the environment at that time [@bib2], [@bib13], [@bib24], [@bib26], [@bib41], [@bib42], [@bib43], [@bib44]. A 2 h separation of the calcium containing products and the CPFX can avoid this interaction. The same logic can be applied for MVs necessitating a gap of about 4 h between CPFX and intake of MV. If the co-administration of other drugs or food ingested decreases absorption or bioavailability of CPFX, it potentially increases the risk of infection treatment failure and a drug producing sub-therapeutic actions for a long time leads to development of antimicrobial resistance against that particular antibiotic. Thus, the potency of a renowned antibiotic becomes greatly hindered due to drug--drug and drug--food interactions.

5. Conclusions {#s0065}
==============

Drug--food and drug--drug interactions are matters of concern since the therapeutic efficacy and bioavailability of renowned drugs get greatly suppressed. Moreover, severe adverse drug reactions may also be precipitated. Our current research showed a significant reduction in the bioavailability of popular antibiotic CPFX on interactions with MVs, calcium tablets and milk. Thus, to prevent sub-therapeutic effects and protect against development of anti-microbial resistance, patients should consider taking CPFX and other Ca-containing medicaments at a lag period of 2 h and above. The same solution can be applicable to other dairy and milk products. For MVs, a lag period of at least 4 h is recommended.

The UV-HPLC analytical methodology followed the estimation of CPFX elimination under different study conditions was found to be simple, reliable and cost-effective. Determination of IVIVC based on urinary excretion data showed that dissolution studies can serve as a bio-waiver for expensive human trials and hence the developed methods can be suitable substitutes for bioequivalence studies.

Appendix A. Supplementary materials {#s0075}
===================================
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